- Home
- CMCL vs CHRS Comparison
CMCL vs CHRS Comparison
Compare CMCL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMCL
- CHRS
- Stock Information
- Founded
- CMCL 1992
- CHRS 2010
- Country
- CMCL Jersey
- CHRS United States
- Employees
- CMCL N/A
- CHRS N/A
- Industry
- CMCL Precious Metals
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMCL Basic Materials
- CHRS Health Care
- Exchange
- CMCL Nasdaq
- CHRS Nasdaq
- Market Cap
- CMCL 586.0M
- CHRS 159.2M
- IPO Year
- CMCL N/A
- CHRS 2014
- Fundamental
- Price
- CMCL $31.81
- CHRS $1.53
- Analyst Decision
- CMCL Strong Buy
- CHRS Strong Buy
- Analyst Count
- CMCL 1
- CHRS 4
- Target Price
- CMCL $28.00
- CHRS $4.51
- AVG Volume (30 Days)
- CMCL 295.9K
- CHRS 1.3M
- Earning Date
- CMCL 11-10-2025
- CHRS 11-05-2025
- Dividend Yield
- CMCL 1.75%
- CHRS N/A
- EPS Growth
- CMCL 432.25
- CHRS N/A
- EPS
- CMCL 1.92
- CHRS 1.55
- Revenue
- CMCL $204,738,000.00
- CHRS $272,209,000.00
- Revenue This Year
- CMCL $41.68
- CHRS N/A
- Revenue Next Year
- CMCL N/A
- CHRS $109.48
- P/E Ratio
- CMCL $16.58
- CHRS $0.98
- Revenue Growth
- CMCL 28.06
- CHRS 52.33
- 52 Week Low
- CMCL $8.81
- CHRS $0.66
- 52 Week High
- CMCL $33.50
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- CMCL 67.64
- CHRS 74.22
- Support Level
- CMCL $30.01
- CHRS $1.23
- Resistance Level
- CMCL $32.45
- CHRS $1.40
- Average True Range (ATR)
- CMCL 1.52
- CHRS 0.09
- MACD
- CMCL 0.20
- CHRS 0.01
- Stochastic Oscillator
- CMCL 81.12
- CHRS 97.56
About CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. The company's project includes Maligreen and Motapa.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.